EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Review and Updates on Systemic Mastocytosis and Related Entities

Julie Y Li, Christopher B Ryder, Hailing Zhang, Samuel G Cockey iD, Elizabeth Hyjek, Lynn C Moscinski, Elizabeth Sagatys, Jinming Song

Cancers · 28.11.2023 · 15 (23) · 5626

DOI: 10.3390/cancers15235626 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.11.2023. Verfasst von Julie Y Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mast cell disorders range from benign proliferations to systemic diseases that cause anaphylaxis and other diverse symptoms to mast cell neoplasms with varied clinical outcomes. Mastocytosis is the pathologic process of the accumulation of abnormal mast cells in different organs, mostly driven by KIT mutations, and can present as cutaneous mastocytosis, systemic mastocytosis (SM), and mast cell sarcoma. The WHO 5th edition classification divides systemic mastocytosis into bone marrow mastocytosis, indolent systemic mastocytosis, smoldering systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. The new ICC classifies SM slightly differently. The diagnosis of SM requires the integration of bone marrow morphologic, immunophenotypic, and molecular findings, as well as clinical signs and symptoms. Moreover, understanding the wide range of clinical presentations for patients with mast cell disorders is necessary for accurate and timely diagnosis. This review provides an updated overview of mast cell disorders, with a special emphasis on SM, including the latest approaches to diagnosis, prognostic stratification, and management of this rare disease.

Schlagwörter

Stichwörter der Autor:innen

KITWHO 5th Edition Classification of Haematolymphoid Tumours (WHO 5th edition)classificationdiagnosishereditary alpha-tryptasemia (HαT or HAT)mast cell activation syndrome (MCAS)molecularsystemic mastocytosis (SM)the International Consensus Classification (2022 ICC)treatment

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Morsani College of Medicine, University of South Florida Health, Tampa, FL 33602, USA.

ORCID-Profile: Samuel G Cockey

Zitieren

APA

Li, J. Y., Ryder, C. B., Zhang, H., Cockey, S. G., Hyjek, E., Moscinski, L. C., Sagatys, E., & Song, J. (2023). Review and Updates on Systemic Mastocytosis and Related Entities. Cancers, 15(23), 5626. https://doi.org/10.3390/cancers15235626

Vancouver

Li JY, Ryder CB, Zhang H, Cockey SG, Hyjek E, Moscinski LC, et al. Review and Updates on Systemic Mastocytosis and Related Entities. Cancers. 2023;15(23):5626. doi:10.3390/cancers15235626

BibTeX
@article{Li2023,
  author = {Li, Julie Y and Ryder, Christopher B and Zhang, Hailing and Cockey, Samuel G and Hyjek, Elizabeth and Moscinski, Lynn C and Sagatys, Elizabeth and Song, Jinming},
  title = {Review and Updates on Systemic Mastocytosis and Related Entities},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {23},
  pages = {5626},
  doi = {10.3390/cancers15235626}
}
Kostenlos starten →